Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Myfembree Combination |
|---|---|
| Manufacturer | Sumitomo Pharma America, Inc |
| Prescription required | Yes |
Myfembree Combination Tablets,1 x 28(/ (E2) (NETA)) (Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg)
Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg
Description
Myfembree Combination Tablets,1 x 28(/ (E2) (NETA)) (Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg) is a medicine catalog record in the MediPriceHub database. Active ingredient: Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Sumitomo Pharma America,Inc. Therapeutic category: Medicine Library > Oncology Medicines > Uterine Myoma. Pack information: 40 / 1 / 0.5 28. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
MYFEMBREE is a combination of relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated in premenopausal women for the: Limitations of Use Use of MYFEMBREE should be limited to 24 months due to the risk of continued bone loss which may not be reversible. management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids). management of moderate to severe pain associated with endometriosis.How to Use
Use Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg. Pack size: 40 / 1 / 0.5 28. Pack unit: bottle. Manufacturer: Sumitomo Pharma America,Inc. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Uterine Myoma. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Ces informations sont fournies à titre indicatif. Demandez conseil à un professionnel de santé avant d'utiliser un médicament.